Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
Alan B. Sandler(Heidelberg University), L H Einhorn(Heidelberg University), C. Manegold(Heidelberg University), John Nemunaitis(Gradalis (United States)), Claude Denham(Heidelberg University), Anne Gregor(University of Bern), Binh Thanh Nguyen(Heidelberg University), Yvon Cormier(Heidelberg University), Clet Niyikiza(Heidelberg University), K. Mattson(Asklepios Fachkliniken München-Gauting), Martin Palmer(National Cancer Centre Japan), U. Gatzemeier(Ontario Institute for Cancer Research), Joachim von Pawel(Asklepios Fachkliniken München-Gauting)
Cited by 719
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k
Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
|The Lancet Neurology|2018|2.8k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k